#United States #Cambridge #RPTR-1-201 #Repertoire Immune Medicines #fast track designation

Repertoire Immune Medicines Receives FDA Fast Track Designation for RPTR-1-201

Repertoire Immune Medicines, a front-runner in the biotechnology sector, has made significant strides by securing Fast Track Designation from the U.S. Food and Drug Administration (FDA) for their investigational immune therapy, RPTR-1-201. This recognition is pivotal for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (TNBC), particularly those carrying the HLA-A*0201 allele who have limited options following the failure of standard therapies.

About RPTR-1-201

RPTR-1-201 is a state-of-the-art T cell receptor (TCR) bispecific therapy specifically engineered to target tumor cells. The design employs a unique mechanism that directs T cells to specific epitopes on the cancer cells, thereby enhancing the immune response against the tumor. This innovative approach is rooted in the company’s DECODE™ platform, which intricately maps the interaction between TCRs and their corresponding antigenic epitopes, enabling the precise targeting of cancer cells.

Robert Andtbacka, MD, CM, the Chief Medical Officer at Repertoire, emphasized the urgency of new treatment options for patients with advanced TNBC, where the prognosis remains bleak following the progression of the disease. The Fast Track Designation signals the FDA’s acknowledgment of the crucial need for effective treatments in this area, providing a pathway for expedited development and review of RPTR-1-201.

Dr. Anthony Coyle, the President and Head of Research and Development at Repertoire, stated that the acknowledgment from the FDA reflects the company’s ongoing commitment to innovative cancer treatments. The TCR bispecific molecule in RPTR-1-201 merges a tumor-selective TCR with an anti-CD3 domain, promoting improved T cell engagement and redirection against tumors. This is a further testament to the effectiveness of their targeted therapeutic strategies.

Clinical Development and Future Plans

Currently, RPTR-1-201 is undergoing clinical evaluation in a Phase 1/2 trial, assessing its efficacy both as a monotherapy and in conjunction with anti-PD-1 therapy for patients with various advanced solid tumors. The trial, registered under ClinicalTrials.gov Identifier NCT07293754, aims to elucidate the therapeutic potential of RPTR-1-201 further.

With this Fast Track Designation, Repertoire can engage in more frequent dialogues with the FDA, potentially facilitating a rolling review process for its future marketing applications, assuming it meets the required criteria. This designation underscores the dedication of Repertoire to reduce the timeline for bringing groundbreaking treatments to market for patients in dire need of options.

About Repertoire Immune Medicines

Repertoire Immune Medicines is at the forefront of clinical-stage biotechnology, harnessing human immune responses to craft groundbreaking therapies targeting cancer and autoimmune disorders. Backed by a proprietary DECODE platform, the company is poised to translate revolutionary insights into practical, off-the-shelf immune medicines. Their partnerships with industry giants like Bristol Myers Squibb, Genentech, Pfizer, and Eli Lilly further highlight their commitment to advancing healthcare solutions.

Founded in 2019 by Flagship Pioneering, Repertoire operates out of Cambridge, Massachusetts, and Zurich, Switzerland. For further updates on their research and advancements, interested parties can visit their official website or their profiles on LinkedIn and X.